Table 2.

Factors associated with tumor necrosis factor-α inhibitor treatment success.

VariableCompeting Risk HR (95% CI)**
Female sex1.36 (0.75, 2.47)
White1.60 (0.84, 3.05)
Age at diagnosis ≤ 6 yrs1.30 (0.68, 2.49)
JIA2.41 (1.28, 4.56)
  Oligo-JIA5.93 (2.15, 16.36)
  ANA positive1.67 (0.71, 3.98)
Anterior uveitis2.52 (1.35, 4.69)
Active uveitis at start§1.00 (0.54, 1.85)
Iris synechiae||1.00 (0.46, 2.21)
Pain/redness/photosensitivity0.65 (0.31, 1.39)
≥ 2 prior surgeries2.29 (0.70, 7.54)
≥ 2 prior IMT0.46 (0.18, 1.22)
MTX at start of anti-TNF1.47 (0.56, 3.89)
IMT other than MTX at start0.62 (0.30, 1.30)
Diagnosis to anti-TNF > 1 yr1.41 (0.73, 2.71)
Anti-TNF
  Etanercept1.00 (reference)
  Infliximab1.34 (0.53, 3.43)
  Adalimumab1.07 (0.22, 5.12)
Monoclonal antibody anti-TNF1.33 (0.52, 3.38)
CHOP subcohort0.74 (0.35, 1.58)
  • A HR > 1 is favorable, representing a relatively higher incidence of treatment success. HR with 95% CI that does not cross 1 are in bold text.

  • ** Proportional subhazards analysis, with drug discontinuation for failure or adverse reaction as a competing risk.

  • Data are only available on subjects from CHOP.

  • § Active uveitis, vs uveitis controlled but on corticosteroids, at the onset of anti-TNF.

  • || Synechiae are adhesions between the iris and the lens (posterior) or cornea (anterior).

  • Monoclonal anti-TNF (infliximab or adalimumab) vs etanercept. JIA: juvenile idiopathic arthritis; oligo-JIA: oligoarticular JIA; ANA: antinuclear antibodies; IMT: immunomodulatory therapy; MTX: methotrexate; anti-TNF: tumor necrosis factor-α inhibitor; CHOP: The Children’s Hospital of Philadelphia; SITE: the Systemic Immunosuppressive Therapy for Eye Disease Cohort Study.